/HLS.TO

HLS.TO Stock - HLS Therapeutics Inc.

Q: What is the analyst price target for HLS.TO?

Analyst price target information is not currently available for HLS.TO.

Q: What is HLS.TO's market cap?

Market capitalization information is not currently available for HLS.TO.

Healthcare|Drug Manufacturers - Specialty & Generic|TSX

$4.75-1.25%

$0.06 (-1.25%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $5.23

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HLS.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.95

52W High$5.76

52W Low$3.70

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$56.62M	$63.07M	$61.47M	$60.01M	$56.11M
Gross Profit	$47.62M	$55.45M	$56.49M	$56.04M	$52.48M
Gross Margin	84.1%	87.9%	91.9%	93.4%	93.5%
Operating Income	$-7,686,000	$-10,349,000	$-13,440,000	$-6,240,000	$-11,256,000
Net Income	$-19,655,000	$-27,531,000	$-23,598,000	$-13,117,000	$-15,331,000
Net Margin	-34.7%	-43.6%	-38.4%	-21.9%	-27.3%
EPS	$-0.62	$-0.85	$-0.73	$-0.41	$-0.48

Company Overview

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

Visit Website

Earnings History & Surprises

HLS.TO

Beat Rate

22%

Last 18 quarters

Avg Surprise

-45.9%

EPS vs Estimate

Beats / Misses

4/13

1 met exactly

Latest EPS

$-0.17

Q4 2025

EPS Surprise History

Q1 24

-88.9%

$-0.17vs$-0.09

Q2 24

-5.6%

$-0.19vs$-0.18

Q3 24

0.0%

$-0.18vs$-0.18

Q4 24

+25.0%

$-0.15vs$-0.20

Q1 25

+44.4%

$-0.10vs$-0.18

Q2 25

-40.0%

$-0.14vs$-0.10

Q3 25

-38.8%

$-0.12vs$-0.09

Q4 25

-148.6%

$-0.17vs$-0.07

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Mar 11, 2026	—	—	—	—
Q4 2025	Nov 13, 2025	$-0.07	$-0.17	-148.6%	✗ MISS
Q3 2025	Aug 14, 2025	$-0.09	$-0.12	-38.8%	✗ MISS
Q2 2025	May 7, 2025	$-0.10	$-0.14	-40.0%	✗ MISS
Q1 2025	Mar 12, 2025	$-0.18	$-0.10	+44.4%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.20	$-0.15	+25.0%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.18	$-0.18	0.0%	= MET
Q2 2024	May 9, 2024	$-0.18	$-0.19	-5.6%	✗ MISS
Q1 2024	Mar 14, 2024	$-0.09	$-0.17	-88.9%	✗ MISS
Q4 2023	Nov 9, 2023	$-0.09	$-0.21	-133.3%	✗ MISS
Q3 2023	Aug 10, 2023	$-0.12	$-0.29	-141.7%	✗ MISS
Q2 2023	May 11, 2023	$-0.11	$-0.18	-63.6%	✗ MISS
Q1 2023	Mar 16, 2023	$-0.07	$-0.20	-185.7%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.13	$-0.14	-7.7%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.07	$-0.14	-100.0%	✗ MISS
Q2 2022	May 5, 2022	$-0.10	$-0.11	-10.0%	✗ MISS
Q1 2022	Mar 17, 2022	$-0.10	$-0.13	-30.0%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.11	$-0.06	+45.5%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.15	$-0.07	+53.3%	✓ BEAT

Frequently Asked Questions about HLS.TO

What is HLS.TO's current stock price?

HLS Therapeutics Inc. (HLS.TO) is currently trading at $4.75 per share. The stock has moved -1.25% today.

What is the analyst price target for HLS.TO?

No analyst price targets are currently available for this stock.

What sector is HLS Therapeutics Inc. in?

HLS Therapeutics Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the TSX exchange.

What is HLS.TO's market cap?

HLS Therapeutics Inc. has a market capitalization of $0.15 billion, making it a small-cap company.

Does HLS.TO pay dividends?

No, HLS Therapeutics Inc. does not currently pay a dividend to shareholders.